{"transactions":[{"id":2607082,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-08-11T18:20:52.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested."}],"balance_after":6562,"derivative":{"exercise_price":1.11,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-050976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121050976/doc4.xml","form_type":"4"}},{"id":2607081,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-08-11T18:20:52.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1880,"price":30.2113,"value":56797.244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-050976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121050976/doc4.xml","form_type":"4"}},{"id":2607080,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-08-11T18:20:52.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":5620,"price":29.7382,"value":167128.684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":6210,"source":{"system":"sec-edgar","filing":"0001209191-21-050976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121050976/doc4.xml","form_type":"4"}},{"id":2607079,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-08-11T18:20:52.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":7500,"price":1.11,"value":8325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":11830,"source":{"system":"sec-edgar","filing":"0001209191-21-050976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121050976/doc4.xml","form_type":"4"}},{"id":2636331,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-07-12T19:36:02.000Z","date":"2021-07-12","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is fully vested."}],"balance_after":14062,"derivative":{"exercise_price":1.11,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-046362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121046362/doc4.xml","form_type":"4"}},{"id":2636330,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-07-12T19:36:02.000Z","date":"2021-07-12","kind":"sale","acquired":false,"shares":400,"price":24.73,"value":9892.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $24.65 and the highest price at which shares were sold was $24.79."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-046362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121046362/doc4.xml","form_type":"4"}},{"id":2636329,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-07-12T19:36:02.000Z","date":"2021-07-12","kind":"sale","acquired":false,"shares":7100,"price":23.877,"value":169526.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.62 and the highest price at which shares were sold was $24.40. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":4730,"source":{"system":"sec-edgar","filing":"0001209191-21-046362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121046362/doc4.xml","form_type":"4"}},{"id":2636328,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-07-12T19:36:02.000Z","date":"2021-07-12","kind":"exercise","acquired":true,"shares":7500,"price":1.11,"value":8325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":11830,"source":{"system":"sec-edgar","filing":"0001209191-21-046362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121046362/doc4.xml","form_type":"4"}},{"id":2672274,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-06-11T16:10:17.000Z","date":"2021-06-10","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":21562,"derivative":{"exercise_price":1.11,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-039810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121039810/doc4.xml","form_type":"4"}},{"id":2672273,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-06-11T16:10:17.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":400,"price":30.9037,"value":12361.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $30.765 and the highest price at which shares were sold was $30.95."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-039810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121039810/doc4.xml","form_type":"4"}},{"id":2672272,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-06-11T16:10:17.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":1100,"price":30.0051,"value":33005.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.67 and the highest price at which shares were sold was $30.57."}],"balance_after":4730,"source":{"system":"sec-edgar","filing":"0001209191-21-039810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121039810/doc4.xml","form_type":"4"}},{"id":2672271,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-06-11T16:10:17.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":6000,"price":29.1469,"value":174881.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $28.64 and the highest price at which shares were sold was $29.62. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":5830,"source":{"system":"sec-edgar","filing":"0001209191-21-039810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121039810/doc4.xml","form_type":"4"}},{"id":2672270,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-06-11T16:10:17.000Z","date":"2021-06-10","kind":"exercise","acquired":true,"shares":7500,"price":1.11,"value":8325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":11830,"source":{"system":"sec-edgar","filing":"0001209191-21-039810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121039810/doc4.xml","form_type":"4"}},{"id":2718881,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-05-11T19:56:54.000Z","date":"2021-05-10","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":29062,"derivative":{"exercise_price":1.11,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-031891","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121031891/doc4.xml","form_type":"4"}},{"id":2718880,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-11T19:56:54.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":700,"price":27.6621,"value":19363.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.42 and the highest price at which shares were sold was $27.95."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-031891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121031891/doc4.xml","form_type":"4"}},{"id":2718879,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-11T19:56:54.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":2501,"price":26.8745,"value":67213.1245,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $26.41 and the highest price at which shares were sold was $27.32."}],"balance_after":5030,"source":{"system":"sec-edgar","filing":"0001209191-21-031891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121031891/doc4.xml","form_type":"4"}},{"id":2718878,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-11T19:56:54.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":4299,"price":26.0683,"value":112067.6217,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $25.40 and the highest price at which shares were sold was $26.39. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":7531,"source":{"system":"sec-edgar","filing":"0001209191-21-031891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121031891/doc4.xml","form_type":"4"}},{"id":2718877,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-11T19:56:54.000Z","date":"2021-05-10","kind":"exercise","acquired":true,"shares":7500,"price":1.11,"value":8325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":11830,"source":{"system":"sec-edgar","filing":"0001209191-21-031891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121031891/doc4.xml","form_type":"4"}},{"id":2750531,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"exercise","acquired":false,"shares":5104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":36562,"derivative":{"exercise_price":1.11,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":5104},"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750530,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"exercise","acquired":false,"shares":2396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2026-01-27","underlying":"Common Stock","underlying_shares":2396},"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750529,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":545,"price":28.6549,"value":15616.9205,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $28.32 and the highest price at which shares were sold was $29.25."}],"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750528,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":2883,"price":27.669,"value":79769.727,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.27 and the highest price at which shares were sold was $28.18."}],"balance_after":4875,"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750527,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":4072,"price":26.8284,"value":109245.2448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $26.25 and the highest price at which shares were sold was $27.24. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":7758,"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750526,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"exercise","acquired":true,"shares":5104,"price":1.11,"value":5665.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":11830,"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2750525,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-13T17:19:18.000Z","date":"2021-04-12","kind":"exercise","acquired":true,"shares":2396,"price":0.84,"value":2012.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":6726,"source":{"system":"sec-edgar","filing":"0001209191-21-026457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121026457/doc4.xml","form_type":"4"}},{"id":2772106,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-25T19:23:33.000Z","date":"2021-03-25","kind":"exercise","acquired":false,"shares":4330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":2396,"derivative":{"exercise_price":0.84,"expiration_date":"2026-01-27","underlying":"Common Stock","underlying_shares":4330},"source":{"system":"sec-edgar","filing":"0001209191-21-023086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121023086/doc4.xml","form_type":"4"}},{"id":2772105,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-03-25T19:23:33.000Z","date":"2021-03-25","kind":"exercise","acquired":true,"shares":4330,"price":0.84,"value":3637.2,"ownership":{"direct":true},"balance_after":4330,"source":{"system":"sec-edgar","filing":"0001209191-21-023086","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121023086/doc4.xml","form_type":"4"}},{"id":2800315,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-09T16:04:49.000Z","date":"2021-03-08","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":6726,"derivative":{"exercise_price":0.84,"expiration_date":"2026-01-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-21-018935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121018935/doc4.xml","form_type":"4"}},{"id":2800314,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-03-09T16:04:49.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":200,"price":38.34,"value":7668.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $38.23 and the highest price at which shares were sold was $38.45."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-018935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121018935/doc4.xml","form_type":"4"}},{"id":2800313,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-03-09T16:04:49.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":4490,"price":37.306,"value":167503.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.94 and the highest price at which shares were sold was $37.63."}],"balance_after":200,"source":{"system":"sec-edgar","filing":"0001209191-21-018935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121018935/doc4.xml","form_type":"4"}},{"id":2800312,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-03-09T16:04:49.000Z","date":"2021-03-08","kind":"sale","acquired":false,"shares":2810,"price":36.4792,"value":102506.552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $35.93 and the highest price at which shares were sold was $36.91. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":4690,"source":{"system":"sec-edgar","filing":"0001209191-21-018935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121018935/doc4.xml","form_type":"4"}},{"id":2800311,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-03-09T16:04:49.000Z","date":"2021-03-08","kind":"exercise","acquired":true,"shares":7500,"price":0.84,"value":6300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-21-018935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121018935/doc4.xml","form_type":"4"}},{"id":2843514,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":2096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The stock option vests as to 1/48 of the total shares monthly beginning June 28, 2020 until the option is fully vested on May 28, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":14678,"derivative":{"exercise_price":9.57,"expiration_date":"2030-06-27","underlying":"Common Stock","underlying_shares":2096},"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843513,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":3797,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":72869,"derivative":{"exercise_price":7.26,"expiration_date":"2030-02-26","underlying":"Common Stock","underlying_shares":3797},"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843512,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":false,"shares":9107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option is fully vested."}],"balance_after":14226,"derivative":{"exercise_price":0.84,"expiration_date":"2026-01-27","underlying":"Common Stock","underlying_shares":9107},"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843511,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":400,"price":37.875,"value":15150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.74 and the highest price at which shares were sold was $38.01."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843510,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":1000,"price":36.924,"value":36924.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.58 and the highest price at which shares were sold was $37.30."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843509,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":6400,"price":35.9888,"value":230328.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $35.53 and the highest price at which shares were sold was $36.50."}],"balance_after":1400,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843508,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":4553,"price":35.0217,"value":159453.8001,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $34.52 and the highest price at which shares were sold was $35.50."}],"balance_after":7800,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843507,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":2647,"price":34.188,"value":90495.636,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $33.51 and the highest price at which shares were sold was $34.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4."}],"balance_after":12353,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843506,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":2096,"price":9.57,"value":20058.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843505,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":3797,"price":7.26,"value":27566.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":12904,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2843504,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-02-22T16:06:20.000Z","date":"2021-02-18","kind":"exercise","acquired":true,"shares":9107,"price":0.84,"value":7649.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":9107,"source":{"system":"sec-edgar","filing":"0001209191-21-012661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121012661/doc4.xml","form_type":"4"}},{"id":2863835,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":136380,"kind":"person","name":"Beaurang Pierre","position":1,"cik":"0001817226","reported_name":"Beaurang Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-12T19:21:13.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/48 of the total shares monthly beginning March 11, 2021 until the option is fully vested on February 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":38.97,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-010437","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817226/000120919121010437/doc4.xml","form_type":"4"}}]}